Main Products
Chugai’s prescribed medicines are categorized into oncology and Specialty (excl. oncology).
View details in a PDF format.
Oncology Area
Alecensa® (alectinib) | ALK inhibitor |
---|---|
Avastin® (bevacizumab) | Anti-VEGF humanized monoclonal antibody |
FoundationOne® CDx Cancer Genomic Profile FoundationOne® Liquid CDx Cancer Genomic Profile |
- |
Gazyva® (obinutuzumab) | Anti-CD20 humanized monoclonal antibody |
Herceptin® (trastuzumab) | Anti-HER2 humanized monoclonal antibody |
Kadcyla® (trastuzumab emtansine) | Anti-HER2 antibody-tubulin polymerization inhibitor conjugate |
Perjeta® (pertuzumab) | Anti-HER2 humanized monoclonal antibody |
Polivy® (polatuzumab vedotin) | Antimicrotubule binding anti-CD79b monoclonal antibody |
Rituxan® (rituximab) | Anti-CD20 monoclonal antibody |
Rozlytrek® (entrectinib) | Tyrosine kinase inhibitor |
Tecentriq® (atezolizumab) | Anti-PD-L1 humanized monoclonal antibody |
Specialty Area (excl. Oncology)
Actemra® (tocilizumab) | Humanized anti-human IL-6 receptor monoclonal antibody |
---|---|
CellCept® (mycophenolate mofetil) | Immunosuppressant |
Edirol® (eldecalcitol) | Osteoporosis agent (Active vitamin D3 derivative) |
Enspryng® (satralizumab) | pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody |
Evrysdi® (risdiplam) | Spinal muscular atrophy agent |
Hemlibra® (emicizumab) | Anti-coagulation factor IXa/X humanized bispecific monoclonal antibody |
Mircera® (epoetin beta pegol) | Long-acting erythropoiesis-stimulating agent |
Oxarol® (maxacalcitol) | Agent for secondary hyperparathyroidism |
Ronapreve® (casirivimab/imdevimab) | anti-SARS-CoV-2 monoclonal antibody |
Tamiflu® (oseltamivir) | Anti-influenza agent |
Vabysmo® (faricimab) | Anti VEGF/anti Ang-2 bispecific antibody |